Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NX 5948

Next Previous
X
Search
Drug Profile

NX 5948

Alternative Names: [14C]-NX-5948; NX-5948

Latest Information Update: 24 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nurix
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Preclinical Autoimmune disorders; Rhabdomyosarcoma; Rheumatoid arthritis
  • No development reported Graft-versus-host disease

Most Recent Events

  • 19 Dec 2024 NX 5948 receives Fast Track designation for Waldenstrom's macroglobulinaemia [PO] (Late-stage disease, Second-line therapy or greater) in USA
  • 09 Dec 2024 Pharmacodynamics data from a preclinical trials in Non-Hodgkin's lymphoma released by Nurix Therapeutics
  • 09 Dec 2024 Safety and efficacy data from a phase-I clinical trialsin Chronic lymphocytic leukaemia and small lymphocytic leukaemia released by Nurix Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top